Literature DB >> 19716385

Diazepam and cocaine potentiate brain stimulation reward in C57BL/6J mice.

Carolin J Straub1, William A Carlezon, Uwe Rudolph.   

Abstract

The curve-shift variant of the intracranial self-stimulation paradigm (ICSS) is particularly useful to study drug effects on motivated behavior while distinguishing them from effects on the capability to perform the task. In this study we examined the effects of cocaine and diazepam on reward-facilitation and response rate in C57BL/6J mice, the most frequently used mouse line to study genetic modifications. Both cocaine and diazepam potentiated the rewarding effects of lateral hypothalamic brain stimulation in a dose-dependent manner and increased the rate of responding. Interestingly, the maximum decrease in ICSS thresholds was comparable for both drugs, suggesting a similar ability to affect reward and motivation despite different effects on brain reward systems.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19716385     DOI: 10.1016/j.bbr.2009.08.025

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  20 in total

1.  Reduction of fear-potentiated startle by benzodiazepines in C57BL/6J mice.

Authors:  Kiersten S Smith; Edward G Meloni; Karyn M Myers; Ashlee Van't Veer; William A Carlezon; Uwe Rudolph
Journal:  Psychopharmacology (Berl)       Date:  2010-10-05       Impact factor: 4.530

2.  Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.

Authors:  Jason M Wiebelhaus; Travis W Grim; Robert A Owens; Matthew F Lazenka; Laura J Sim-Selley; Rehab A Abdullah; Micah J Niphakis; Robert E Vann; Benjamin F Cravatt; Jenny L Wiley; S Stevens Negus; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2014-11-14       Impact factor: 4.030

3.  Effects of gaboxadol on the expression of cocaine sensitization in rats.

Authors:  Nora Siegal Silverman; Susanna Popp; Vincent Vialou; Konstantin Astafurov; Eric J Nestler; Diana Dow-Edwards
Journal:  Exp Clin Psychopharmacol       Date:  2016-02-22       Impact factor: 3.157

Review 4.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

5.  Lateral septum inhibition reduces motivation for cocaine: Reversal by diazepam.

Authors:  Caroline B Pantazis; Gary Aston-Jones
Journal:  Addict Biol       Date:  2019-03-21       Impact factor: 4.280

Review 6.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

7.  Diazepam blocks 50 kHz ultrasonic vocalizations and stereotypies but not the increase in locomotor activity induced in rats by amphetamine.

Authors:  Gisele de Oliveira Guaita; Debora Dalla Vecchia; Roberto Andreatini; Donita L Robinson; Rainer K W Schwarting; Claudio Da Cunha
Journal:  Psychopharmacology (Berl)       Date:  2018-03-23       Impact factor: 4.530

8.  Effects of the neuroactive steroid allopregnanolone on intracranial self-stimulation in C57BL/6J mice.

Authors:  A Leslie Morrow; C J Malanga; Eric W Fish; Buddy J Whitman; Jeff F DiBerto; J Elliott Robinson
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

9.  Neural basis of benzodiazepine reward: requirement for α2 containing GABAA receptors in the nucleus accumbens.

Authors:  Elif Engin; Konstantin I Bakhurin; Kiersten S Smith; Rochelle M Hines; Lauren M Reynolds; Wannan Tang; Rolf Sprengel; Stephen J Moss; Uwe Rudolph
Journal:  Neuropsychopharmacology       Date:  2014-02-19       Impact factor: 7.853

10.  Negative allosteric modulation of GABAA receptors inhibits facilitation of brain stimulation reward by drugs of abuse in C57BL6/J mice.

Authors:  Matthew E Tracy; Matthew L Banks; Keith L Shelton
Journal:  Psychopharmacology (Berl)       Date:  2015-11-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.